Charged Multivesicular Body Protein 2B (CHMP2B) (N-Term) Antikörper

Antigen: Charged Multivesicular Body Protein 2B (CHMP2B)

Synonyme: DMT1, VPS2B, VPS2-2, CHMP2.5, DKFZp564O123, 1190006E07Rik, RGD1306781, chmp2b, MGC77025, CHMP2B, LOC569532, MGC128858, DKFZp468C162

Epitope: N-Term

Klonalität: Polyklonal

Wirt: Kaninchen

Applikation: Immunhistochemie (IHC), Western Blot (WB)

Produktnummer: ABIN350224

Produktbeschreibung

Weitere Bezeichnung: CHMP2B (Charged multivesicular body protein 2b) (n-terminal)

Swiss-Prot: Q9UQN3

Immunogen: A synthetic peptide from the n-terminal of human CHMP2B (Charged multivesicular body protein 2b, Vacuolar protein sorting associated protein 2-2, Vps2-2) conjugated to an immunogenic carrier protein was used as the immunogen.

Format: Lyophilized

Beschreibung: FUNCTION: Component of the ESCRT-III complex, which is required for multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. The MVB pathway mediates delivery oftransmembrane proteins into the lumen of the lysosome for degradation. The ESCRT-III complex is probably involved in the concentration of MVB cargo. In case of infection, the HIV-1 virus takes advantage of the ESCRT-III complex for budding and exocytic cargos of viral proteins. SUBCELLULAR LOCATION: Cytoplasm, cytosol. TISSUE SPECIFICITY: Widely expressed. Expressed in brain, heart, skeletal muscle, spleen, kidney, liver, small intestine, pancreas, lung, placenta and leukocytes. In brain, it is expressed in cerebellum, cerebral cortex, medulla, spinal chord, occipital lobe, frontal lobe, temporal lobe and putamen. DISEASE: Defects in CHMP2B are the cause of frontotemporal dementia, chromosome 3-linked (FTD3). FTD3 is characterized by an onset of dementia in the late 50's initially characterized by behavioral and personality changes including apathy, restlessness, disinhibition and hyperorality, progressing to stereotyped behaviors, non-fluent aphasia, mutism and dystonia, with a marked lack of insight. The brains of individuals with FTD3 have no distinctive neuropathological features. They show global cortical and central atrophy, but no beta-amyloid deposits. Also known as: Chromatin-modifying protein 2b, CHMP2.5, Vacuolar protein sorting associated protein 2-2, Vps2-2, hVps2-2, Charged multivesicular body protein 2b.

Spezifität: Appears to be specific for CHMP2B.

Anwendungen

Applikationshinweise: IHC, WB. A dilution of 1 : 300 to 1 : 2000 is recommended. The optimal dilution should be determined by the end user. Not tested in other applications.

Reinheit: whole serum

Lagerung: Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Publikationen

Publikationen: Lai, Chou, Chang et al.: "Identification of novel human genes evolutionarily conserved in Caenorhabditis elegans by comparative proteomics." in: Genome research, Vol. 10, Issue 5, pp. 703-13, 2000 (PubMed).

Strack, Calistri, Craig et al.: "AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding." in: Cell, Vol. 114, Issue 6, pp. 689-99, 2003 (PubMed).

Skibinski, Parkinson, Brown et al.: "Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia." in: Nature genetics, Vol. 37, Issue 8, pp. 806-8, 2005 (PubMed).

Nousiainen, Silljue, Sauer et al.: "Phosphoproteome analysis of the human mitotic spindle." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, Issue 14, pp. 5391-6, 2006 (PubMed).

Parkinson, Ince, Smith et al.: "ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B)." in: Neurology, Vol. 67, Issue 6, pp. 1074-7, 2006 (PubMed).